Centennial Wealth Advisory LLC Buys New Position in Amgen Inc. (NASDAQ:AMGN)

Centennial Wealth Advisory LLC bought a new stake in Amgen Inc. (NASDAQ:AMGN) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 1,264 shares of the medical research company’s stock, valued at approximately $407,000.

Other large investors have also recently bought and sold shares of the company. Hershey Financial Advisers LLC bought a new stake in Amgen during the second quarter worth about $30,000. nVerses Capital LLC bought a new stake in shares of Amgen during the 2nd quarter worth approximately $31,000. Bbjs Financial Advisors LLC acquired a new stake in shares of Amgen in the 2nd quarter valued at approximately $33,000. Matrix Trust Co bought a new position in shares of Amgen in the third quarter valued at $36,000. Finally, FSA Wealth Management LLC increased its holdings in Amgen by 182.0% during the first quarter. FSA Wealth Management LLC now owns 141 shares of the medical research company’s stock worth $40,000 after buying an additional 91 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

NASDAQ AMGN traded up $1.65 on Wednesday, hitting $320.94. 245,940 shares of the company’s stock were exchanged, compared to its average volume of 2,402,063. Amgen Inc. has a 52 week low of $260.52 and a 52 week high of $346.85. The stock has a 50-day moving average of $324.12 and a 200-day moving average of $316.64. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The stock has a market cap of $172.45 billion, a price-to-earnings ratio of 40.88, a P/E/G ratio of 2.81 and a beta of 0.60.

Amgen (NASDAQ:AMGN) last released its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. During the same quarter in the previous year, the business posted $4.96 earnings per share. The business’s revenue for the quarter was up 23.2% on a year-over-year basis. Analysts expect that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be given a $2.25 dividend. The ex-dividend date of this dividend is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a yield of 2.80%. Amgen’s dividend payout ratio is currently 115.24%.

Analysts Set New Price Targets

A number of brokerages have recently commented on AMGN. Robert W. Baird reissued an “underperform” rating and issued a $215.00 price objective on shares of Amgen in a research report on Wednesday, September 25th. StockNews.com upgraded Amgen from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Jefferies Financial Group reaffirmed a “buy” rating and set a $380.00 price objective (up from $375.00) on shares of Amgen in a research report on Wednesday, August 7th. UBS Group cut their target price on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating for the company in a research note on Thursday, October 31st. Finally, Sanford C. Bernstein began coverage on shares of Amgen in a research note on Thursday, October 17th. They issued an “outperform” rating and a $380.00 price target on the stock. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $333.50.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.